神経保護剤:パーキンソン病の治療への影響
Khaled Ramadan Algantri1,2, Wael Mohamed2,3, Mohd Hamzah Mohd Nasir4
1Department of Anatomy, Kulliyyah of Medicine, Widad University College, BIM Point, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia.
Current Alzheimer research
|February 16, 2026
まとめ
パーキンソン病は,酸化ストレスと炎症によって引き起こされるニューロンの損失を伴う. 天然化合物は神経保護の有望性を示していますが,パーキンソン病の効果的な治療にはより多くの臨床試験が必要です.
科学分野:
- 神経科学は神経科学である.
- 病理生理学 病理生理学とは
- 薬理学 薬理学とは
背景:
- パーキンソン病 (PD) は,ドーパミナージックニューロン喪失によって特徴づけられる神経変性疾患であり,運動および認知の欠陥を引き起こす.
- 主な病理学的メカニズムには,遺伝的および環境的要因の影響を受けた酸化ストレス,ミトコンドリア機能障害,神経炎症が含まれます.
研究 の 目的:
- パーキンソン病の病理生理学的経路を調べるために.
- PDの進行に対する天然化合物の神経保護の可能性を調査する.
主な方法:
- 酸化ストレス,ミトコンドリア機能障害,神経炎症に焦点を当てて,PDの病理生理学的分析を徹底した.
- レスベラトロール,クルクミン,ジンゼノサイド,メラトニンなどの天然剤の神経保護効果の評価.
主要な成果:
- 酸化ストレス,ミトコンドリア機能障害,神経炎症は,PDにおけるドーパミナージックニューロン変性症候群の中心にある.
- 天然化合物は,PDの管理における潜在的な神経保護効果を示しています.
結論:
- パーキンソン病の現在の治療法は,病気を修正する能力が欠けている.
- PDの補助療法としての天然化合物の安全性と有効性を検証するために,さらなる臨床試験が不可欠です.
関連する概念動画
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:15Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
01:37Neural Regulation
43.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.5K
01:22Alzheimer's Disease: Treatment
994
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
994
01:29Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.6K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.6K